COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Protocol To Evaluate Patient Measurements After Ultrasonic Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01373827
Recruitment Status : Completed
First Posted : June 15, 2011
Last Update Posted : March 26, 2012
Information provided by:
Sound Surgical Technologies, LLC.

Brief Summary:
Patients enrolled in this study will come from the Investigator's patient population and be ordinarily suitable for treatment using the MC1 device. The treatment they receive will be no different if they participate than if they do not. The study is only to observe the patients before, during and after their usual treatment.

Condition or disease Intervention/treatment
Patients Treated With VaserShape MC1 Device: VASERShape MC1

Layout table for study information
Study Type : Observational
Actual Enrollment : 7 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Protocol To Evaluate Patient Measurements After Ultrasonic Treatment.
Study Start Date : June 2011
Actual Primary Completion Date : March 2012
Actual Study Completion Date : March 2012

Group/Cohort Intervention/treatment
MC1 Subjects Device: VASERShape MC1
Use of the VASERShape MC1 device as part of routine practice

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
All subjects presenting to the investigator for treatment using the MC1 are potential study candidates and will be screened for eligibility. Every effort will be made to establish eligibility of the participants before enrollment. Subjects who do not meet all inclusion/exclusion criteria will not be enrolled. Enrollment in the study occurs at the time the patient is randomized to the assigned treatment.

Inclusion Criteria:

  1. Healthy Female between 20 and 50 years of age, inclusive, on the day of enrolment.
  2. Has a BMI between 20 and 30 kg/m2.
  3. Is to be treated in the posterior thigh / saddlebag area using the MC1.
  4. Has never been treated with the MC1 before.
  5. Females who are post menopausal or using a medically acceptable form of birth control prior to study enrollment and during the course of the study. (i.e., condoms with spermicide, oral contraceptives contraceptive implants etc.)

Exclusion Criteria:

  1. Subject is lactating, has a positive pregnancy test within 7 days of planned study procedure (for female subjects of child-bearing potential), or intends to become pregnant during the study.
  2. Currently enrolled in another device or drug study that has not completed the required follow-up period, or has completed all other study-required follow-up less than 30 days before enrolment in this study.
  3. Keloid scars, hypertorphic scars or a history of abnormal healing.
  4. Any known bruising disorder, anticoagulative / thromboembolic condition , hemorrhagic (bleeding) status or use of anti coagulants.
  5. Tissue ischemia in the area to be treated.
  6. Suffering from concurrent conditions such as liver or kidney disorders, Hypertension or abnormally high blood pressure.
  7. High cholesterol and/or diabetes.
  8. Active collagen vascular disease (e.g. fibromyalgia, panniculitis, lupus etc.).
  9. Epilepsy.
  10. Tuberculosis.
  11. Auxiliary electric organs (such as pacemakers), metal or myoelectric prosthesis.
  12. Suffering from Endocrine syndromes or thyroid hyperfunction.
  13. Active skin infection, any infection in the treated area within the last 30 days or skin disease in the area to be treated (e.g. eczema, psoriasis, urticaria, dermographism).
  14. Bone, muscle or joint disease, dysfunction or healing in the area to be treated.
  15. Malignancy in the area to be treated.
  16. Laminectomy in the area to be treated.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01373827

Layout table for location information
United States, New York
Laser & Skin Surgery Center of New York
New York, New York, United States, 10016
Sponsors and Collaborators
Sound Surgical Technologies, LLC.
Layout table for additonal information
Responsible Party: Roy G Geronemus, MD, Laser & Skin Surgery Center of New York Identifier: NCT01373827    
Other Study ID Numbers: SST2011-2
First Posted: June 15, 2011    Key Record Dates
Last Update Posted: March 26, 2012
Last Verified: March 2012
Keywords provided by Sound Surgical Technologies, LLC.: